These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 33608749)

  • 1. Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice.
    Bonaldo G; Montanaro N; AlbertoVaccheri ; Motola D
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1225-1234. PubMed ID: 33608749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dermatologic Adverse Events Associated With Chimeric Antigen Receptor T-Cell Therapy: A Pharmacovigilance Analysis of the FDA Reporting System.
    Storgard R; Dusza S; Shouval R; Scordo M; Markova A
    Transplant Cell Ther; 2024 Oct; 30(10):1035.e1-1035.e7. PubMed ID: 38945480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy.
    Goldman A; Maor E; Bomze D; Liu JE; Herrmann J; Fein J; Steingart RM; Mahmood SS; Schaffer WL; Perales MA; Shouval R
    J Am Coll Cardiol; 2021 Nov; 78(18):1800-1813. PubMed ID: 34711339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric antigen receptor T-cells safety: A pharmacovigilance and meta-analysis study.
    Dolladille C; Ederhy S; Ezine E; Choquet S; Nguyen LS; Alexandre J; Moslehi JJ; Dechartres A; Salem JE
    Am J Hematol; 2021 Sep; 96(9):1101-1111. PubMed ID: 34057232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
    Alsuliman T; Drieu La Rochelle L; Campidelli A; Duléry R; Fayard A; Mamez AC; Mear JB; Schneider PO; Trevet A; Vicente C; Yakoub-Agha I
    Bull Cancer; 2021 Dec; 108(12S):S65-S71. PubMed ID: 33678408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.
    Ahmed N; Wesson W; Lutfi F; Porter DL; Bachanova V; Nastoupil LJ; Perales MA; Maziarz RT; Brower J; Shah GL; Chen AI; Oluwole OO; Schuster SJ; Bishop MR; McGuirk JP; Riedell PA
    Blood Adv; 2024 Oct; 8(20):5346-5354. PubMed ID: 39042880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurological adverse events following CAR T-cell therapy: a real-world analysis.
    Gajra A; Zettler ME; Phillips EG; Klink AJ; Jonathan K Kish ; Fortier S; Mehta S; Feinberg BA
    Immunotherapy; 2020 Oct; 12(14):1077-1082. PubMed ID: 32808566
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review.
    Wu X; Zhang X; Xun R; Liu M; Sun Z; Huang J
    Front Immunol; 2021; 12():693200. PubMed ID: 34290712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.
    Rejeski K; Perez A; Sesques P; Hoster E; Berger C; Jentzsch L; Mougiakakos D; Frölich L; Ackermann J; Bücklein V; Blumenberg V; Schmidt C; Jallades L; Fehse B; Faul C; Karschnia P; Weigert O; Dreyling M; Locke FL; von Bergwelt-Baildon M; Mackensen A; Bethge W; Ayuk F; Bachy E; Salles G; Jain MD; Subklewe M
    Blood; 2021 Dec; 138(24):2499-2513. PubMed ID: 34166502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database.
    Fusaroli M; Isgrò V; Cutroneo PM; Ferrajolo C; Cirillo V; Del Bufalo F; Raschi E; Poluzzi E; Trifirò G
    Drug Saf; 2022 Aug; 45(8):891-908. PubMed ID: 35829913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptor T-cell therapy-induced nervous system toxicity: a real-world study based on the FDA Adverse Event Reporting System database.
    Ren X; Zhang G; Li G; Wang Y
    BMC Cancer; 2024 Jan; 24(1):10. PubMed ID: 38166723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety assessment of anti-B cell maturation antigen chimeric antigen receptor T cell therapy: a real-world study based on the FDA adverse event reporting system database.
    Liu W; Lin S; Zhu X; Yin L; Liu Q; Lei S; Feng B
    Front Immunol; 2024; 15():1433075. PubMed ID: 39290710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?
    Huguet M; Raimond V; Kaltenbach E; Augusto V; Perrier L
    Bull Cancer; 2021 Dec; 108(12):1170-1180. PubMed ID: 34561025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updated insights on cardiac risks of CD19-directed chimeric antigen receptor T-cell therapy: a pharmacovigilance study.
    Zhai Y; Hu F; Zhu B; Xu J; Guo X; Shi W; Zhou X; Zheng Y; Xu X; Ye X; He J; Xu F
    Immunotherapy; 2023 Apr; 15(6):443-456. PubMed ID: 36951157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.
    Levin A; Shah NN
    Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunotherapy with CAR-T cells in paediatric haematology-oncology].
    Mirones I; Moreno L; Patiño-García A; Lizeaga G; Moraleda JM; Toribio ML; Pérez-Martínez A; ;
    An Pediatr (Engl Ed); 2020 Jul; 93(1):59.e1-59.e10. PubMed ID: 32107177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Practical aspects of the application of CAR T cells and management of their toxicities].
    Bücklein V; Blumenberg V; Subklewe M
    Dtsch Med Wochenschr; 2021 Sep; 146(17):1129-1137. PubMed ID: 34448189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.
    Westin JR; Kersten MJ; Salles G; Abramson JS; Schuster SJ; Locke FL; Andreadis C
    Am J Hematol; 2021 Oct; 96(10):1295-1312. PubMed ID: 34310745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Summary of US Food and Drug Administration Chimeric Antigen Receptor (CAR) T-Cell Biologics License Application Approvals From a Statistical Perspective.
    Lin X; Lee S; Sharma P; George B; Scott J
    J Clin Oncol; 2022 Oct; 40(30):3501-3509. PubMed ID: 35613410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of Chimeric Antigen Receptor T-cell Therapy in Adults.
    Dudley CV; Baer B; Simons RM
    Semin Oncol Nurs; 2019 Oct; 35(5):150930. PubMed ID: 31561845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.